Johnson & Johnson (JNJ) reported results in line with expectations in Q1 FY2026 on revenue of $24.1B versus the $23.6B estimate (+9.9% YoY) and EPS of $2.70. The next Johnson & Johnson (JNJ) earnings date is Jul 15, 2026. Below is the full Johnson & Johnson earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
Johnson & Johnson (JNJ) Earnings Analysis — key stats
Next earnings date
Jul 15, 2026
Latest reported quarter
Q1 FY2026
Earnings verdict
In line
EPS beat rate
5 of last 8 (quarters above estimate)
Avg next-day move
±1.4% (over the last 8 reports)
Post-earnings direction
Up 6 / Down 2 (of the last 8 reports)
Implied move (next report)
±4.7% (options-derived · into Jul 15, 2026)
Revenue
$24.1B (vs $23.6B est · +1.9% surprise · +9.9% YoY)
EPS
$2.70 (vs $2.68 est · +0.7% surprise · -53.2% YoY)
Share price
$263.04 (+3.6%)
Market cap
$633.2B
Johnson & Johnson (JNJ) Earnings Analysis — beat / miss history
Quarter
Revenue
EPS
EPS surprise
Next-day move
Verdict
Q2 2026
$24.1B vs $23.6B est
$2.70 vs $2.68 est
+0.7%
+0.3%
In line
Q1 2026
$24.6B vs $24.1B est
$2.46 vs $2.46 est
+0.0%
+0.1%
In line
Q4 2025
$24.0B vs $23.8B est
$2.80 vs $2.76 est
+1.4%
+0.1%
In line
Q3 2025
$23.7B vs $22.9B est
$2.77 vs $2.68 est
+3.4%
+5.0%
Beat
Q2 2025
$21.9B vs $21.6B est
$2.77 vs $2.58 est
+7.4%
-0.3%
Mixed
Q1 2025
$22.5B vs $22.4B est
$2.04 vs $1.99 est
+2.5%
-1.0%
Mixed
Q4 2024
$22.5B vs $22.2B est
$2.42 vs $2.21 est
+9.5%
+1.7%
Mixed
Q3 2024
$22.4B vs $22.3B est
$2.82 vs $2.71 est
+4.1%
+2.9%
Mixed
What you'll find
Next Johnson & Johnson (JNJ) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Johnson & Johnson reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Johnson & Johnson (JNJ)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Johnson & Johnson's next earnings date?
Johnson & Johnson's (JNJ) next scheduled earnings date is Jul 15, 2026. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Johnson & Johnson (JNJ) beat or miss earnings?
In Q1 FY2026, Johnson & Johnson (JNJ) posted in-line results — revenue of $24.1B versus the $23.6B estimate (+1.9% surprise) and EPS of $2.70 versus $2.68 expected (+0.7% surprise). Magnisto decodes every Johnson & Johnson (JNJ) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
How often does Johnson & Johnson beat earnings estimates?
Over its last 8 reported quarters, Johnson & Johnson (JNJ) beat Wall Street EPS estimates 5 times, most recently a in-line result in Q2 2026. Magnisto tracks every Johnson & Johnson (JNJ) quarter's revenue and EPS versus consensus and grades each one Beat, Miss, In-line or Mixed at a unified ±2% threshold.
How much does Johnson & Johnson stock move after earnings?
Over its last 8 quarterly reports, Johnson & Johnson (JNJ) moved an average of ±1.4% the day after earnings — ranging from -1.0% (Q1 2025) to +5.0% (Q3 2025). The stock rose after 6 of those 8 reports and fell after 2. Heading into its next report on Jul 15, 2026, options-implied volatility is pricing in a move of roughly ±4.7% (derived). Magnisto tracks the realized post-earnings move for every Johnson & Johnson (JNJ) quarter alongside the beat/miss verdict — past moves don't predict the next one.
What is the forecast for Johnson & Johnson (JNJ) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Johnson & Johnson (JNJ), anchored to the current $263.04 share price, so you can weigh the bull, base and bear cases for Johnson & Johnson side by side.
Is Johnson & Johnson (JNJ) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Johnson & Johnson fits your own thesis and risk profile. This is research, not investment advice.